APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01 Inhalation of APN01 to directly target SARS-CoV-2 virus in respiratory tract, the lung and tissue itselfPrimary objective is to evaluate safety and tolerability of inhaled APN01Phase 1 trial to enroll about 40 healthy volunteersAdditional US Phas.
Researchers have found that the indigenous Andaman tribes of Onge Jarawa, who live in isolation and follow strict endogamy, are highly susceptible to the Covid-19 infection.
DGAP-News: APEIRON Biologics AG / Key word(s): Study12.10.2021 / 08:00 The issuer is solely responsible for the content of this announcement.APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01 Inhalation of APN01 to directly target SARS-CoV-2 virus in respiratory tract, the lung and tissue itself.